Simvastatin: Two decades in a circle

Cardiovascular Therapeutics

Volumn 26, Issue 2, 2008, Pages 166-178

  Kolovou, Genovefa D ^a   Vasiliadis, Ioannis ^a   Anagnostopoulou, Katerina ^a   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Pleiotropic effects; Simvastatin; Studies

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FLUINDOSTATIN; GELATINASE B; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PRAVASTATIN; SIMVASTATIN; STROMELYSIN; TIROFIBAN; TRIACYLGLYCEROL; UNINDEXED DRUG; VASCULOTROPIN; VERAPAMIL;

ACUTE CORONARY SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL FUNCTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIUM; HEMOSTASIS; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; LIPID OXIDATION; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SMOOTH MUSCLE FIBER;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPOPROTEINS, LDL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SIMVASTATIN; TREATMENT OUTCOME;

EID: 46749101796     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2008.00047.x     Document Type: Review

References (125)

1. Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 286 : 64 70.
2. Amsden GW, Kuye O, Wei GC (2002) A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 42 : 444 9.
3. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P (1995) Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 75 : 71B 74B.
4. Antons KA, Williams CD, Baker SK, Phillips PS (2006) Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 119 : 400 409.
5. Ballantyne CM (2005) Cholesterol, lipids, and statins. Tex Heart Inst J 32 : 378 379.
6. Bays H (2006) Statin safety: An overview and assessment of the data - 2005. Am J Cardiol 97 : 6C 26C.
7. Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, Santoli E, Norbiato G (1997) Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 79 : 84 87.
8. Bottorff MB (2006) Statin safety and drug interactions: Clinical implications. Am J Cardiol 97 : 27C 31C.
9. Boucher K, Siegel CS, Sharma P, Hauschka PV, Solomon KR (2006) HMG-CoA reductase inhibitors induce apoptosis in pericytes. Microvasc Res 71 : 91 102.
10. Calabro P, Yeh ET (2005) The pleiotropic effects of statins. Curr Opin Cardiol 20 : 541 546.
11. Ceylan A, Karasu C, Aktan F, Ozansoy G (2004) Simvastatin treatment restores vasoconstriction and the inhibitory effect of LPC on endothelial relaxation via affecting oxidizing metabolism in diabetic rats. Diabetes Nutr Metab 17 : 203 210.
12. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO (2006) Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. Faseb J 20 : 1706 1708.
13. Chang JT, Staffa JA, Parks M, Green L (2004) Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13 : 417 426.
14. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA (2005) Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 118 : 618 624.
15. Cheng AY, Leiter LA (2006) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol 21 : 400 404.
16. Cheng K., Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, Waters MG (2006) Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 103 : 6682 6687.
17. Cohen DE, Anania FA, Chalasani N (2006) An assessment of statin safety by hepatologists. Am J Cardiol 97 : 77C 81C.
18. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361 : 2005 2016.
19. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, et al. 2002) Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: Two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106 : 2884 2887.
20. Criddle DN, Madeira SV, Soares de Moura R (2003) Endothelium-dependent and -independent vasodilator effects of eugenol in the rat mesenteric vascular bed. J Pharm Pharmacol 55 : 359 365.
21. Davidson MH (2002) A look to the future: New treatment guidelines and a perspective on statins. Am J Med 112 (Suppl 8A 34S 41S.
22. Davidson MH (2006) Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 5 : 145 156.
23. Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T (2006) Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 97 : 223 228
24. De Caterina R, Cipollone F, Filardo FP, Zimarino M, Bernini W, Lazzerini G, Bucciarelli T, Falco A, Marchesani P, Muraro R, et al. 2002) Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: No further effect of vitamin E. Circulation 106 : 2543 2549.
25. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ (2002) Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40 : 2117 2121.
26. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, et al. 2004) Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292 : 1307 1316.
27. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F (2003) HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23 : 58 63.
28. Dumont JM (1993) Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS). Control Clin Trials 14 : 209 228.
29. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A (1994) Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89 : 2519 2524.
30. Fenton JW 2nd., Brezniak DV, Ofosu FA, Shen GX, Jacobson JR, Garcia JG (2005) Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord 5 : 115 120.
31. Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M (2002) Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164 : 179 185.
32. Fukazawa I, Uchida N, Uchida E, Yasuhara H (2004) Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 57 : 448 455.
33. Genser B, Marz W (2006) Low density lipoprotein cholesterol, statins and cardiovascular events: A meta-analysis. Clin Res Cardiol 95 : 393 404.
34. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, Kesaniemi YA, Faergeman O (2000) The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : A substudy of the Scandinavian Simvastatin Survival Study. Circulation 101 : 1366 1371.
35. Girona J, La Ville AE, Sola R, Plana N, Masana L (1999) Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 83 : 846 851.
36. Giroux LM, Davignon J, Naruszewicz M (1993) Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1165 : 335 338.
37. Giurgea AG, Margeta C, Maca T, Rezaie-Majd A, Bucek RA, Manavi M, Afarideh R, Minar E, Baghestanian M (2006) Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. J Cardiovasc Pharmacol 47 : 30 36.
38. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, Thillet J (2002) Atorvastatin lowers lipoprotein (a) but not apolipoprotein (a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 164 : 305 311.
39. Grodos D, Tonglet R (1994) Scandinavian Simvastatin Study (4S). Lancet 344 : 1768.
40. Gruber A, Nasser K, Smith R, Sharma JC, Thomson GA (2006) Diabetes prevention: Is there more to it than lifestyle changes? Int J Clin Pract 60 : 590 594.
41. Guven GS, Atalar E, Yavuz B, Beyazit Y, Kekilli M, Kilicarslan A, Sahiner L, Oz G, Ozer N, Aksoyek S, et al. 2006) Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia. J Natl Med Assoc 98 : 627 630.
42. Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P (1995) Effect of simvastatin on Lp (a) concentrations. Clin Cardiol 18 : 261 267.
43. Hamsten A, Wiman B, de Faire U, Blomback M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313 : 1557 1563.
44. Hartung D, Sarai M, Petrov A, Kolodgie F, Narula N, Verjans J, Virmani R, Reutelingsperger C, Hofstra L, Narula J (2005) Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. J Nucl Med 46 : 2051 2056.
45. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S (1998) Effects of the 3-hydroxy-3-methylglutaryl- CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 : 2711 2719.
46. Hess DC, Demchuk AM, Brass LM, Yatsu FM (2000) HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention. Neurology 54 : 790 796.
47. Holdaas H, Hagen E, Asberg A, Lund K, Hartman A, Vaidyanathan S, Prasad P, He YL, Yeh CM, Bigler H, et al. 2006) Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 44 : 163 171.
48. Horiuchi N, Maeda T (2006) Statins and bone metabolism. Oral Dis 12 : 85 101.
49. Hu H, Sung A, Zhao G, Shi L, Qiu D, Nishimura T, Kao PN (2006) Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun 339 : 59 64.
50. Imamura R, Ichimaru N, Moriyama T, Shi Y, Namba Y, Nonomura N, Matsumiya K, Toki K, Takahara S, Okuyama A (2005) Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus. Clin Transplant 19 : 616 621.
51. Isley WL, Harris WS, Miles JM (2006) The effect of high-dose simvastatin on free fatty acid metabolism in patients with type 2 diabetes mellitus. Metabolism 55 : 758 762.
52. Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94 : 1140 1146.
53. Jamal SM, Eisenberg MJ, Christopoulos S (2004) Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 147 : 956 965.
54. Jensen LO, Thayssen P, Pedersen KE, Haghfelt T (2006) Short- and long-term influence of diet and simvastatin on brachial artery endothelial function. Int J Cardiol 107 : 101 106.
55. Jiang JL, Jiang DJ, Tang YH, Li NS, Deng HW, Li YJ (2004) Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 25 : 893 901.
56. Johnson C, Galis ZS (2004) Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 24 : 54 60.
57. Jones PH, Davidson MH (2005) Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 : 120 122.
58. Kanda H, Hamasaki K, Kubo K, Tateishi S, Yonezumi A, Kanda Y, Yamamoto K, Mimura T (2002) Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 29 : 2024 2026.
59. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, Kim DS, Jeong EM, Park GS, Choi IS, et al. 2002) Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22 : e19 e23.
60. Kolovou G (2001) The treatment of coronary heart disease: An update. Part 3: Statins beyond cholesterol lowering. Curr Med Res Opin 17 : 34 37.
61. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL (1989) HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp (a) levels. Circulation 80 : 1313 1319.
62. Kunieda Y, Nakagawa K, Nishimura H, Kato H, Ukimura N, Yano S, Kawano H, Kimura S, Nakagawa M, Tsuji H (2003) HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res 110 : 227 234.
63. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, et al. 2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110 : 1933 1939.
64. Law M, Rudnicka AR (2006) Statin safety: A systematic review. Am J Cardiol 97 : 52C 60C.
65. Lee AJ, Maddix DS (2001) Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 35 : 26 31.
66. Lee TS, Chang CC, Zhu Y, Shyy JY (2004) Simvastatin induces heme oxygenase-1: A novel mechanism of vessel protection. Circulation 110 : 1296 1302.
67. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S (2004) Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110 : 2336 2341.
68. Lopes-Virella MF, Mironova M, Stephan E, Durazo-Arvizu R, Virella G (2004) Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care 27 : 908 913.
69. Luan Z, Chase AJ, Newby AC (2003) Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23 : 769 775.
70. Ludwig S, Dharmalingam S, Erickson-Nesmith S, Ren S, Zhu F, Ma GM, Zhao R, Fenton JW 2nd., Ofosu FA, Velthuis HT, et al. 2005) Impact of simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetes mellitus. Diabetes Res Clin Pract 70 : 110 118.
71. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, Ardal S, Alter DA, Laupacis A (2006) Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: Modelling study. BMJ 332 : 1419.
72. Mason RP (2006) Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens (Greenwich) 8 : 31 38 quiz 40.
73. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY (2004) A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 172 : 2903 2908.
74. Meyers CD, Liu P, Kamanna VS, Kashyap ML (2007) Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: An in vitro model of the niacin flush. Atherosclerosis 192 : 253 258.
75. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96 : 4211 4218.
76. Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J (2006) The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: A SILHOUETTE trial sub-study. Curr Med Res Opin 22 : 343 350.
77. Mohrschladt MF, de Maat MP, Westendorp RG, Smelt AH (2001) C-reactive protein in patients with familial hypercholesterolemia: No effect of simvastatin therapy. Atherosclerosis 157 : 491 494.
78. Montaner J (2005) Treatment with statins in the acute phase of ischemic stroke. Expert Rev Neurother 5 : 211 221.
79. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH (1997) Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types. Biochim Biophys Acta 1345 : 259 268.
80. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN (2003) Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108 : 1640 1645.
81. Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ (2003) Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 163 : 1837 1841.
82. Ortego M, Gomez-Hernandez A, Vidal C, Sanchez-Galan E, Blanco-Colio LM, Martin-Ventura JL, Tunon J, Diaz C, Hernandez G, Egido J (2005) HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol 45 : 468 475.
83. Parnetti L, Caso V, Lanari A, Saggese E, Sebastianelli M, Tayebati SK, Amenta F (2006) Stroke prevention and statin treatment. Clin Exp Hypertens 28 : 335 344.
84. Parra JL, Reddy KR (2003) Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 7 : 415 433.
85. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, et al. 2006) Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98 : 361 369.
86. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G (2004) Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. Am J Cardiol 94 : 720 724.
87. Pedersen TR, Tobert JA (2004) Simvastatin: A review. Expert Opin Pharmacother 5 : 2583 2596.
88. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, et al. 2000) Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 86 : 257 262.
89. Perez-Guerrero C, Marquez-Martin A, Herrera MD, Marhuenda E, Alvarez deSotomayor M (2005) Regulation of vascular tone from spontaneously hypertensive rats by the HMG-CoA reductase inhibitor, simvastatin. Pharmacology 74 : 209 215.
90. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH (2002) Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 : 1447 1452.
91. Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J (2004) Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27 : 1735 1740.
92. Rabadi MH, Blass J (2004) Randomized clinical stroke trials in 2003. Curr Atheroscler Rep 6 : 257 260.
93. Robinson JG (2007) Simvastatin: Present and future perspectives. Expert Opin Pharmacother 8 : 2159 2172.
94. Rung E, Friberg PA, Bergh C, Billig H (2006) Depletion of substrates for protein prenylation increases apoptosis in human periovulatory granulosa cells. Mol Reprod Dev 73 : 1277 1283.
95. Scanu AM, Hinman J (2002) Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein (a) levels. Lipids 37 : 439 444.
96. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay JF, Hennekens CH (2006) Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 Inhibition by Statins [PARIS] study). Am J Cardiol 97 : 1332 1336.
97. Shammas NW, Kapalis MJ, Deckert J, Harris M, Dippel EJ, Labroo A, McKinney D (2003) Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: Experience of a community lipid clinic and safety review from the literature. Prev Cardiol 6 : 189 194.
98. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME (1999) Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: Evidence for smooth muscle cell-mediated vascular calcification. Circulation 100 : 2168 2176.
99. Shiomi M, Yamada S, Ito T (2005) Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits. Atherosclerosis 178 : 287 294.
100. Solfrizzi V, Capurso C, Colacicco AM, D'Introno A, Fontana C, Capurso SA, Torres F, Gadaleta AM, Koverech A, Capurso A, et al. 2006) Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein (a) serum levels in patients with type 2 diabetes mellitus. Atherosclerosis 188 : 455 461.
101. Soma MR, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, Paoletti R (1993) HMG CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 13 : 571 578.
102. Stalenhoef AF, Stuyt PM, de Graaf J (1997) Effects of ketoconazole on plasma lipids and lipoprotein (a) in familial hypercholesterolaemia, compared with simvastatin. Neth J Med 51 : 10 15.
103. Steinberg D (2006) Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy. J Lipid Res 47 : 1339 1351.
104. Stenestrand U, Wallentin L (2001) Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285 : 430 436.
105. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364 : 771 777.
106. Sukhova GK, Williams JK, Libby P (2002) Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22 : 1452 1458.
107. Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H (2006) Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 35 : 722 729.
108. Thallinger C, Urbauer E, Lackner E, Graselli U, Kostner K, Wolzt M, Joukhadar C (2005) The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients. Int J Clin Pharmacol Ther 43 : 551 557.
109. Thompson PD, Clarkson PM, Rosenson RS (2006) An assessment of statin safety by muscle experts. Am J Cardiol 97 : 69C 76C.
110. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 : 481 487.
111. Uchiyama T, Atsuta H, Utsugi T, Ohyama Y, Nakamura T, Nakai A, Nakata M, Maruyama I, Tomura H, Okajima F, et al. 2006) Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis 188 : 265 273.
112. van Haelst PL, van Doormaal JJ, Asselbergs FW, van Roon AM, Veeger NJ, Henneman MM, Smit AJ, Tervaert JW, May JF, Gans RO (2003) Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. Clin Sci (Lond) 104 : 627 632.
113. van Tits LJ, Smilde TJ, van Wissen S, de Graaf J, Kastelein JJ, Stalenhoef AF (2004) Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med 52 : 177 184.
114. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF (2003) Long term statin treatment reduces lipoprotein (a) concentrations in heterozygous familial hypercholesterolaemia. Heart 89 : 893 896.
115. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ (2002) Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165 : 361 366.
116. Vasudevan AR, Hamirani YS, Jones PH (2005) Safety of statins: Effects on muscle and the liver. Cleve Clin J Med 72 : 990 993, 996 1001.
117. Wada H, Mori Y, Kaneko T, Wakita Y, Minamikawa K, Ohiwa M, Tamaki S, Yokoyama N, Kobayashi T, Deguchi K, et al. 1992) Hypercoagulable state in patients with hypercholesterolemia: Effects of pravastatin. Clin Ther 14 : 829 834.
118. Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S, et al. 1993) Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 44 : 112 116.
119. Wierzbicki AS, Crook MA, Nair DR, Mikhailidis DP, Winder AF (2000) More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia. Atherosclerosis 148 : 204.
120. Wilhelmsen L, Pyorala K, Wedel H, Cook T, Pedersen T, Kjekshus J (2001) Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 22 : 1119 1127.
121. Wilson SH, Chade AR, Feldstein A, Sawamura T, Napoli C, Lerman A, Lerman LO (2003) Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol Dial Transplant 18 : 703 709.
122. Wolfe ML, Vartanian SF, Ross JL, Bansavich LL, Mohler ER 3rd., Meagher E, Friedrich CA, Rader DJ (2001) Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 87 : 476 479, A7.
123. Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A (2006) Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 185 : 63 70.
124. Yang X, Wang L, Zeng H, Dubey L, Zhou N, Pu J (2006) Effects of simvastatin on NF-kappa B-DNA binding activity and monocyte chemoattractant protein-1 expression in a rabbit model of atherosclerosis. J Huazhong Univ Sci Technolog Med Sci 26 : 194 198.
125. Yeung AC, Tsao P (2002) Statin therapy: Beyond cholesterol lowering and antiinflammatory effects. Circulation 105 : 2937 2938.